Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers
Study Details
Study Description
Brief Summary
Oral anticoagulants that are widely used for the treatment of thrombo-embolic disease exert their effect by blocking the recycling of vitamin K. Vitamin K acts as a co-factor in the posttranslational carboxylation of vitamin K-dependent proteins such as osteocalcin and matrix-gla protein. It is important to quantify the dose-response relationship of the interaction between vitamin K and oral anticoagulants and to investigate at what dosage vitamin K will interfere with oral anticoagulants in a clinically relevant way.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
From all K-vitamins, menaquinone-7 has been identified as the most effective cofactor for the carboxylation reaction of Gla-proteins. In this respect it is important to quantify the dose-response relationship of the interaction between oral anticoagulants and menaquinone-7. The primary objective of the study is to demonstrate at what menaquinone-7 intake the vitamin will interfere with oral anticoagulants in a clinically relevant way. Clinically relevant is defined as a decrease in level of anticoagulation that would require a change in oral anticoagulant treatment in order to stay within target levels. Secondary objective of the study is to investigate changes in carboxylation level of osteocalcin and matrix-gla protein after menaquinone-7 supplementation during the oral anticoagulation treatment period. This will demonstrate whether during oral anticoagulation menaquinone-7 will be transported preferentially to the liver or to other target tissues.
Study Design
Outcome Measures
Primary Outcome Measures
- changes in level anticoagulation [10 weeks]
Secondary Outcome Measures
- changes in carboxylation level of osteocalcin and matrix-gla protein [10 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy male and female adults between 18 and 45 years of age.
-
Subjects of normal body weight and height according to BMI < 30
-
Subject has given written consent to take part in the study
Exclusion Criteria:
-
Subjects with (a history of) of coagulation disorders
-
Subjects with (a history of) metabolic or gastrointestinal disease
-
Subjects using (multi)-vitamin supplements containing vitamin K
-
Subjects presenting chronic inflammatory diseases
-
Subjects using any medication 3 months prior to the study (e.g. corticoĻd treatment, oral anticoagulants)
-
Subjects using oral anticonception
-
Subject with (a history of) soy allergy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Maastricht University | Maastricht | Netherlands | 6200 MD |
Sponsors and Collaborators
- Maastricht University
Investigators
- Principal Investigator: Cees Vermeer, PhD, Maastricht University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MEC 07-3-032